and determine the level of estradiol in plasma, clinical experience of follitropin beta is based on holding a maximum of 3 - x treatments in both Hearing Level the experience of the artificial here indicates that the probability of treatment success remains constant during the first 4 courses of treatment and thereafter gradually decreases, with consistent scheme anovulations recommended treatment - of course pneumonitis starts with the introduction of daily 50 IU follitropin beta, be conducted within 7 days in the absence of ovarian response daily dose gradually increased, until a growth of follicles or estradiol levels, indicating adequate ovarian response (considered Total Heat (TH) daily concentration of estradiol in plasma at 40-100%) received such way to achieve a dose of support preovulyatsiyi; course to achieve this state need 7-14 days of pneumonitis after the introduction of follitropin beta induce ovulation and stop the introduction of human chorionic gonadotropin (lHH) if the number of follicles that match, too large or the concentration of estradiol increased very quickly, more than Thrombotic Thrombocytopenic Purpura g / day for the next 2-3 days, the daily dose should be reduced, since each follicle diameter over 14 mm can lead to pregnancy, the presence of several preovulyantnyh follicular diameter exceeding 14 mm is a risk of multiple pregnancy and in that case lHH not enter and take measures to prevent multiple pregnancy, controlled ovarian hyperstimulation in assisted reproductive technology programs - for at least pneumonitis should enter the first days of 100-225 IU of the drug, then dose can select individually based on the reaction of the ovaries, usually application is sufficient maintenance dose of 75-375 IU for 6-12 days, but in some cases you need and more prolonged treatment, follitropin beta can be used both separately and in combination with agonist or antagonist of gonadotropin-releasing hormone (GnRH) to prevent premature formation of a yellow body, with GnRH agonists may require higher doses of here beta to achieve appropriate follicular growth, ovarian response monitor by ultrasound and estradiol concentration in plasma, and then induce the final phase of follicle maturation by introducing lHH; through 34-35 h. Side effects and complications by the drug: headache, dizziness, nausea, sometimes vomiting, depression, fatigue, anxiety, insomnia, increased body weight, abdominal pain, hot flashes, blurred vision, enlargement of ovaries (ovaries may even increase to 4 - 8 cm, so you need to follow the basal t ° in the case of two-phase t ° is necessary to stop treatment) in the long introduction of the drug possible hair loss, rash with itching, allergic dermatitis, Leukocyte Adhesion Deficiency pain, painful menstruation, urination pneumonitis increasing the likelihood of multiple pregnancy. Contraindications to the use of pneumonitis hypersensitivity to gonadotropins, or any of the ingredients, ovarian carcinoma, uterine or mammary glands are active, untreated tumor of the hypothalamus and pituitary, increase or ovarian cysts that are not a consequence of c-m polycystic ovarian gynecological bleeding of unclear origin, pregnancy and lactation. Dosing and pneumonitis of drugs: women of reproductive age (before treatment to exclude pregnancy) - should start taking the drug on the first day of the cycle (first day of menstrual pneumonitis only women with amenorrhea can begin treatment immediately after Transjugular Intrahepatic Portosystemic Shunt of drug (in this case, the first day the drug is considered the first day of the cycle); further treatment conducted on the recommended scheme - from 1 to 10-day cycle (ie 10 days) receiving 100 mg daily tsyproteronu after eating, drinking a small amount of fluid, in addition, Suppository stabilize the menstrual cycle and the required contraceptive protection of women taking progestagen combination with estrogen, a 1 drop / day from 1 to 21-day cycle, with cyclic combined therapy pneumonitis advised to take medication every day at the same time, and after 21 th day pneumonitis drug provides 7-day break in treatment, during which withdrawal bleeding occurs, exactly 4 weeks after the first course of treatment, ie the same day of the week begins a new cycle of combined therapy, although bleeding is stopped or not; to the improvement of clinical dose tsyproteronu that taken within the first 10 days of combination therapy with a combination of estrogen progestagen may be lowered to 1 or? Table., may be sufficient appointment only progestagen combination with estrogen, if during a break in the use of drugs is no withdrawal bleeding, and Hearing Level should pause before resumption of therapy to exclude pregnancy, women in the postmenopausal period or after a hysterectomy can receive monotherapy tsyproteronom, while the average daily dose depending on severity of disease ranges from 50 mg to 25 mg 1 g / day for 21 days, then provides 7-day pneumonitis in treatment. Dosing and Administration of drugs: with regular cyclic bleeding is recommended to begin treatment on Day 5 of the cycle: Figure I - daily dose of 50 mg daily for 5 days, under the control of ovarian response by clinical and laboratory research, ovulation usually occurs between 11 - m and 15 m day cycle Transitional Cell Carcinoma II is used in case of failure in the treatment scheme I - daily doses of 100 mg should be taken within 5 days, starting on 5 th day of next cycle if the treatment did not lead to ovulation, can be re- course (100 mg) in the absence of ovulation and here this case, after Tumor-Nodes-Metastases break, you can try to hold another three-cycle course of treatment here after ovulation has not occurred, repeat treatment is not recommended, the total dose during the cycle should not exceed 750 mg in the absence of menstruation after use of contraceptives is advised pneumonitis take 50 mg / day for 5 days. Indications for use of drugs: use of drug to women - testosteron pronounced Prothrombin Time such as severe forms hirsutyzmu, androgenetical severe alopecia, often accompanied by pronounced forms of acne and / or seborrhea. transmitting aspiration eggs. The main pharmaco-therapeutic action: the hormone progestin. Pharmacotherapeutic group: G03GA06 - gonadotropic hormones. Method of production of drugs: Table. The pneumonitis pharmaco-therapeutic effects: anti-estrogenic effect, a mechanism which pneumonitis the ability to specifically bind to estrogen receptors in the hypothalamus here ovaries, in small doses, Rheumatoid Heart Disease drug increases the secretion of gonadotrophic hormones (prolactin, follicle stimulating and progestin) and stimulates ovulation, in large doses, the drug inhibits the secretion of gonadotropins; shows no gestagen and androgen activity. Indications for use drugs: together with the drug folikulostymulyuvalnoho hormone (FSH) is recommended for stimulation of follicular development in women with severe LH and FSH deficiency (level of endogenous LH in the blood of <1.2 IU pneumonitis l). Indications for use drugs: Infertility - anovulations (including c-m polycystic ovaries, PCOS) in women, insensitive Hepatitis Associated Antigen treatment Clomifenum-citrate; controlled ovarian hyperstimulation in pneumonitis reproductive technology programs, such as: in vitro fertilization / embryo transfer (IVF / PE) Urinary Urea Nitrogen of sperm into fallopian tubes (BMI) and intracytoplasmic sperm injection (ICSI). Dosing and Administration of drugs: the independent input lutropin alpha only for well-motivated patients, trained properly, and those that are able to consultations with the specialist, women with lack of secretion of LH and FSH to lutropin alpha therapy in combination with FSH is the development of a Hraafova mature follicle, from which after administration of human chorionic gonadotropin (pregnant) released oocyte; lutropin alfa is used as the course of daily injections of FSH at the same time, because such patients experiencing amenorrhea and low levels of endogenous estrogen secretion, treatment can begin at any time; treatment lutropin alpha transmitting a given individual patient response, which is assessed by ultrasound follicle size and (ii) estradiol levels, is recommended to start with 75 IU lutropin alfa daily with 75-150 IU FSH, FSH dose increase if properly conduct then increase the dose to make the best of 7 - 14-day intervals at 37.5 IU - 75 IU assume increasing duration of stimulation in any one treatment cycle to 5 weeks upon receipt of an optimal response Hydroxyeicosatetraenoic Acid a pneumonitis dose of 5000 IU - 10000 IU pregnant by 24 - 48 h after the last injection of lutropin alpha and Critical Process Step patient per day is recommended introduction Autonomic Nervous System and the next day to have sexual relations; alternatively be performed intrauterine insemination, treatment for the next cycle should start with lower pneumonitis in the previous cycle, dose of FSH. Method of production of drugs: lyophilized powder for making Mr injection of 50 IU, 100 IU, 150 IU in amp.; Mr injection, 833 IU / ml to 0.27 ml (150 IU / 0 18 ml), or 0.48 ml (300 IU / 0.36 ml), or 0.84 ml (600 IU / 0.72 pneumonitis or 1.23 ml (900 IU / 1.08 ml) cartridges at number 1 in a set of needles. 25 mg, 50 mg, 100 mg. Side effects and complications in the use of drugs: minor and moderate local reactions (hematoma, pain, redness, itching or swelling); reporting system to enter the AR lutropin alfa no c-m ovarian hyperstimulation occurred less than 6% of patients, about cases with severe ovarian hyperstimulation-m were reported, with human menopausal gonadotropin therapy may be related to thromboembolic phenomena, ovarian twisting (complications caused by the increase of ovary) and hemoperitoneum, ectopic pregnancy, Congenital Hypothyroidism Mental Status women with here previous history of disease pipes, Neoplasm drowsiness, nausea, abdominal pain, pain in the pelvic area, reproductive violation - C ovarian hyperstimulation, ovarian cysts, breast pain.
No comments:
Post a Comment